Literature DB >> 34266818

Successful mepolizumab treatment for DRESS-induced refractory eosinophilic myocarditis and concurrent thyroiditis.

Kelvin Truong1,2, Shane Kelly3, Angela Bayly4, Annika Smith5,2.   

Abstract

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a potentially life-threatening adverse drug reaction with a mortality rate of 10%. Interstitial nephritis, pneumonitis, myocarditis, meningitis, thyroiditis and pancreatitis are major causes of morbidity and mortality in this syndrome. Cessation of offending medication is paramount. There is paucity in high quality prospective studies guiding the treatment of DRESS, and there are no published therapeutic clinical trials in the treatment of corticosteroid refractory hypersensitivity myocarditis. The authors present a unique case of ciprofloxacin-induced DRESS with concurrent thyroiditis and refractory eosinophilic myocarditis that required mepolizumab and multiple immunosuppressants for successful treatment. © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dermatology; immunology; skin; thyroiditis; unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2021        PMID: 34266818      PMCID: PMC8286746          DOI: 10.1136/bcr-2021-242240

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  2 in total

1.  Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis.

Authors:  Natsumi Hama; Riichiro Abe; Andrew Gibson; Elizabeth J Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2022-02-15

2.  Treatment with IL5-/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS).

Authors:  Anna Gschwend; Arthur Helbling; Laurence Feldmeyer; Ulrich Mani-Weber; Cordula Meincke; Kristine Heidemeyer; Simon Bossart; Lukas Jörg
Journal:  Allergo J Int       Date:  2022-08-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.